ANCA Vasculitis Pipeline Drugs Insights Report 2025: Emerging Therapies and Innovation Trends by DelveInsight

DelveInsight's "ANCA Vasculitis Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the ANCA Vasculitis Pipeline? Click here to explore the therapies and trials making headlines @ ANCA Vasculitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ANCA Vasculitis Pipeline Report

* On 28 October 2025, Nkarta Inc . conducted a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
* On 27 October 2025, Alexion Pharmaceuticals Inc . announced a study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
* On 27 October 2025, Amgen conducted a study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
* DelveInsight's ANCA Vasculitis Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
* The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, and Staidson Biopharmaceuticals Co., Ltd and others.
* Promising ANCA Vasculitis Therapies such as Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone and Rituximab, Mycophenolate Mofetil, Avacopan , and others.

Want to know which companies are leading innovation in ANCA Vasculitis? Dive into the full pipeline insights @ ANCA Vasculitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The ANCA Vasculitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The ANCA Vasculitis Pipeline Report also highlights the unmet needs with respect to the ANCA Vasculitis.

ANCA Vasculitis Overview

Antineutrophilic cytoplasmic antibody (ANCA) associated Vasculitis are a heterogeneous group of rare autoimmune conditions that causes an inflammation of blood vessels with various manifestations. It includes three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis.

ANCA Vasculitis Emerging Drugs Profile

* Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

* Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

If you're tracking ongoing ANCA Vasculitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ ANCA Vasculitis Treatment Drugs [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The ANCA Vasculitis Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of ANCA Vasculitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ANCA Vasculitis Treatment.
* ANCA Vasculitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* ANCA Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ANCA Vasculitis market.

ANCA Vasculitis Companies

Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, and Staidson Biopharmaceuticals Co., Ltd and others.

ANCA Vasculitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the ANCA Vasculitis Pipeline Report covers it all - check it out now @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the ANCA Vasculitis Pipeline Report

* Coverage- Global
* ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, and Staidson Biopharmaceuticals Co., Ltd and others.
* ANCA Vasculitis Therapies- Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone and Rituximab, Mycophenolate Mofetil, Avacopan , and others.
* ANCA Vasculitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ANCA Vasculitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the ANCA Vasculitis Treatment landscape in this detailed analysis @ ANCA Vasculitis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* ANCA Vasculitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ANCA Vasculitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abatacept: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Sparsentan: Travere Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* ANCA Vasculitis Key Companies
* ANCA Vasculitis Key Products
* ANCA Vasculitis- Unmet Needs
* ANCA Vasculitis- Market Drivers and Barriers
* ANCA Vasculitis- Future Perspectives and Conclusion
* ANCA Vasculitis Analyst Views
* ANCA Vasculitis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anca-vasculitis-pipeline-drugs-insights-report-2025-emerging-therapies-and-innovation-trends-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anca-vasculitis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.